Please ensure Javascript is enabled for purposes of website accessibility
Home / Industry / Health Care / Cognivue to join other heavy hitters in Alzheimer’s study (access required)

Cognivue to join other heavy hitters in Alzheimer’s study (access required)

Rochester’s Cognivue Inc. has been selected by the Global Alzheimer’s Platform (GAP) to participate in its pioneering Bio-Hermes clinical trial study. Also participating in the study are Eli Lilly & Co., AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation and other respected biopharma, technology and nonprofit entities. Bio Hermes is the first platform study to investigate and ...
x

Check Also

RPO receives $100,000 grant to perform for dementia patients (access required)

The Rochester Philharmonic Orchestra has received a $100,000 grant from the Andrew W. Mellon Foundation to support free arts programming ...

Reader Rankings: Health Care

Learn the top winners in the Health Care categories for the Rochester Business Journal’s Reader Rankings awards!

Cognivue studying post-COVID cognitive function (access required)

Rochester neuroscience company Cognivue Inc. has begun a nationwide clinical study to assess post-COVID-19 Syndrome. COG-COVID19 is an open-label, prospective, ...